Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221955 · ClinicalTrials.gov registry record · NA
The Impact of Qualia Gluthathione+ on Blood Glutathione Levels
A NA study, sponsored by Qualia Life Sciences.
- Not yet
- Registry status
- NA
- Development phase
- 54
- Enrollment target
NCT07221955: Clinical Trial NA study, sponsored by Qualia Life Sciences.
NCT07221955 is a NA study that has not yet begun recruiting, run by Qualia Life Sciences. The registered enrollment target is 54 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07221955, a NA study, has not yet begun recruiting, sponsored by Qualia Life Sciences.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 54 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, parallel-group, triple-armed, study evaluating the effects of two distinct Qualia Glutathione+ formulations on Whole Blood Glutathione levels in the blood of healthy adults aged 45-75 years. Approximately 18 participants will be randomized to one of three study arms: Qualia Glutathione+ version 1, Qualia Glutathione+ version 2, or placebo. Each participant will take two or three capsules of their assigned product once daily in the morning, with or without food, over a 20-day period. The primary outcome is the change in blood glutathione levels, assessed via in lab blood collection at baseline and study completion. Secondary endpoints include questionnaires measuring health-related quality of life, fatigue, and cognitive functioning (PROMIS Global Health-10, PROMIS Short Form v1.0 - Fatigue 10a, PROMIS Cognitive Function - Short Form 8a), evaluation of safety and tolerability, and an Overall Experience Questionnaire (Appendices 1, 4-7). All assessments, including electronic questionnaires, are completed remotely without in-person visits.
Primary Outcome
To assess between-group differences in the change in blood Total Glutathione levels from baseline to Day 20 following supplementation with Qualia Glutathione version 1 versus placebo and Qualia Glutathione version 2 versus placebo
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Qualia Glutathione+ version 1
- DIETARY_SUPPLEMENT Qualia Glutathione+ version 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2025-12-02 |
| Est. Completion | 2026-01-25 |
| Phase | NA |
What is known before NCT07221955 opens enrollment
NCT07221955 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07221955 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07221955 about?
NCT07221955 is a clinical study titled "The Impact of Qualia Gluthathione+ on Blood Glutathione Levels". This is a randomized, double-blind, placebo-controlled, parallel-group, triple-armed, study evaluating the effects of two distinct Qualia Glutathione+ formulations on Whole Blood Glutathione levels in the blood of healthy adults aged 45-75 years. Approximately 18 participants will be randomized to o...
What is the current status of trial NCT07221955?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 54 participants. The study started on 2025-12-02. Estimated completion is 2026-01-25.
What interventions are being tested in trial NCT07221955?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Qualia Glutathione+ version 1 (DIETARY_SUPPLEMENT), Qualia Glutathione+ version 2 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07221955?
This trial is sponsored by Qualia Life Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07221955's enrollment target sits among peer trials
54 1268th of 2000 higher than 730 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI